De novo AML patients with favourable–intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened “GO question”

✍ Scribed by Marino Clavio, Fabio Cruciani, Paola Minetto, Fabio Guolo…

• Book ID: 120775837
• Publisher: Springer
• Year: 2013
• Tongue: English
• Weight: 313 KB
• Volume: 92
• Category: Article
• ISSN: 0939-5555
• DOI: 10.1007/s00277-013-1780-7